Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple myeloma, gammopathies

Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway

Leukemia volume 32, pages 2445–2458 (2018)Cite this article

Subjects

Abstract

Macrophages are key mediators of the therapeutic effects exerted by monoclonal antibodies, such as the anti-CD38 antibody MOR202, currently introduced in multiple myeloma (MM) therapy. Therefore, it is important to understand how antibody-mediated effector functions of myeloma-associated macrophages (MAMs) are regulated. Here, we focused on the effects of vitamin D, a known regulator of macrophage effector functions. Consequently, it was the aim of this study to assess whether modulation of the vitamin D pathway alters the tumoricidal activity of MAMs. Here, we demonstrate that MAMs display a defective vitamin D pathway with reduced expression level of CYP27B1 and limited tumoricidal activity which can be restored by the IMiD lenalidomide in vitro. Furthermore, our data indicate that the vitamin D pathway of MAMs from MM patients does recover during an IMiD-containing therapy shown by an improved MOR202-mediated cytotoxic activity of these MAMs against primary MM cells ex vivo. Here, the ex vivo cytotoxic activity could be further enhanced by vitamin D supplementation. These data suggest that vitamin D holds a key role for the effector functions of MAMs and that vitamin D supplementation in IMiD combination trials could further increase the therapeutic efficacy of anti-CD38 antibodies such as MOR202, which remains to be investigated in clinical studies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

    Article  CAS  Google Scholar 

  2. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–57.

    Article  CAS  Google Scholar 

  3. van de Donk NW, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127:681–95.

    Article  Google Scholar 

  4. Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau IW, Einsele H, et al. Phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma. Blood. 2015;126:3035–3035.

    Google Scholar 

  5. Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21:2802–10.

    Article  CAS  Google Scholar 

  6. Endell J, Samuelsson C, Boxhammer R, Strauss S, Steidl S. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma. J Clin Oncol. 2011;29:8078–8078.

    Article  Google Scholar 

  7. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.

    Article  CAS  Google Scholar 

  8. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650–7.

    Article  CAS  Google Scholar 

  9. Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015;126:50–60.

    Article  CAS  Google Scholar 

  10. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659–69.

    Article  CAS  Google Scholar 

  11. Gul N, Babes L, Siegmund K, Korthouwer R, Bogels M, Braster R, et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Investig. 2014;124:812–23.

    Article  Google Scholar 

  12. Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell. 2014;156:590–602.

    Article  CAS  Google Scholar 

  13. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114:3625–8.

    Article  CAS  Google Scholar 

  14. Panchabhai S, Kelemen K, Ahmann G, Sebastian S, Mantei J, Fonseca R. Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia. 2016;30:951–4.

    Article  CAS  Google Scholar 

  15. Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol. 2008;142:492–4.

    Article  Google Scholar 

  16. Xu H, Soruri A, Gieseler RK, Peters JH. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol. 1993;38:535–40.

    Article  CAS  Google Scholar 

  17. Cohen MS, Mesler DE, Snipes RG, Gray TK. 1,25-Dihydroxyvitamin D3 activates secretion of hydrogen peroxide by human monocytes. J Immunol. 1986;136:1049–53.

    CAS  PubMed  Google Scholar 

  18. Bruns H, Buttner M, Fabri M, Mougiakakos D, Bittenbring JT, Hoffmann MH, et al. Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma. Sci Transl Med. 2015;7:282ra247.

    Article  Google Scholar 

  19. Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol. 2014;32:3242–8.

    Article  CAS  Google Scholar 

  20. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-Seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20:1352–60.

    Article  CAS  Google Scholar 

  21. Ng AC, Kumar SK, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol. 2009;84:397–400.

    Article  CAS  Google Scholar 

  22. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.

    Article  CAS  Google Scholar 

  23. Kulling PM, Olson KC, Olson TL, Feith DJ, Loughran TP, Jr. Vitamin D in hematological disorders and malignancies. Eur J Haematol. 2016;98:187–197.

    Article  Google Scholar 

  24. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.

    Article  CAS  Google Scholar 

  25. Gergely P, Nekam K, Lang I, Kalmar L, Gonzalez-Cabello R, Perl A. Ketoconazole in vitro inhibits mitogen-induced blastogenesis, antibody-dependent cellular cytotoxicity, natural killer activity and random migration of human leukocytes. Immunopharmacology. 1984;7:167–70.

    Article  CAS  Google Scholar 

  26. Nakashima T, Sato E, Niwano Y, Kohno M, Muraoka W, Oda T. Inhibitory or scavenging action of ketoconazole and ciclopiroxolamine against reactive oxygen species released by primed inflammatory cells. Br J Dermatol. 2007;156:720–7.

    Article  CAS  Google Scholar 

  27. Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget. 2014;5:11283–96.

    Article  Google Scholar 

  28. Gutierrez-Gonzalez A, Martinez-Moreno M, Samaniego R, Arellano-Sanchez N, Salinas-Munoz L, Relloso M, et al. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood. 2016;128:2241–52.

    Article  CAS  Google Scholar 

  29. Lacey DC, Achuthan A, Fleetwood AJ, Dinh H, Roiniotis J, Scholz GM, et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol. 2012;188:5752–65.

    Article  CAS  Google Scholar 

  30. Bruns H, Bottcher M, Qorraj M, Fabri M, Jitschin S, Dindorf J, et al. CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D. Leukemia. 2016;31:985–988.

    Article  Google Scholar 

  31. Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29:2039–49.

    Article  CAS  Google Scholar 

  32. Stoeckler JD, Stoeckler HA, Kouttab N, Maizel AL. 1alpha,25-Dihydroxyvitamin D3 modulates CD38 expression on human lymphocytes. J Immunol. 1996;157:4908–17.

    CAS  PubMed  Google Scholar 

  33. Drozdenko G, Heine G, Worm M. Oral vitamin D increases the frequencies of CD38+ human B cells and ameliorates IL-17-producing T cells. Exp Dermatol. 2014;23:107–12.

    Article  CAS  Google Scholar 

  34. Bauvois B, Durant L, Laboureau J, Barthelemy E, Rouillard D, Boulla G, et al. Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II. J Interferon Cytokine Res. 1999;19:1059–66.

    Article  CAS  Google Scholar 

  35. Kishimoto H, Hoshino S, Ohori M, Kontani K, Nishina H, Suzawa M, et al. Molecular mechanism of human CD38 gene expression by retinoic acid. Identification of retinoic acid response element in the first intron. J Biol Chem. 1998;273:15429–34.

    Article  CAS  Google Scholar 

  36. Mihara K, Yoshida T, Ishida S, Takei Y, Kitanaka A, Shimoda K, et al. All-trans retinoic acid and interferon-alpha increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors. Blood Cancer J. 2016;6:e421.

    Article  CAS  Google Scholar 

  37. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Investig. 2008;118:2427–37.

    CAS  PubMed  Google Scholar 

  38. Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. Eur J Haematol. 2013;90:263–72.

    Article  CAS  Google Scholar 

  39. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106:2169–74.

    Article  CAS  Google Scholar 

  40. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13:5784–9.

    Article  CAS  Google Scholar 

  41. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008;26:440–6.

    Article  CAS  Google Scholar 

  42. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117:1605–13.

    Article  CAS  Google Scholar 

  43. Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol. 2005;61:10–7.

    Article  CAS  Google Scholar 

  44. Steiger J, Stephan A, Inkeles MS, Realegeno S, Bruns H, Kroll P, et al. Imatinib triggers phagolysosome acidification and antimicrobial activity against Mycobacterium bovis Bacille Calmette-Guerin in glucocorticoid-treated human macrophages. J Immunol. 2016;197:222–32.

    Article  CAS  Google Scholar 

  45. Kraaij MD, van der Kooij SW, Reinders ME, Koekkoek K, Rabelink TJ, van Kooten C, et al. Dexamethasone increases ROS production and T cell suppressive capacity by anti-inflammatory macrophages. Mol Immunol. 2011;49:549–57.

    Article  CAS  Google Scholar 

  46. Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, et al. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol. 2015;33:1482–90.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

HB was supported by Wilhelm-Sander Foundation, by the SFB TR 221 (project B12), and by the SFB 1181 (project B04) from the German Research Foundation. This research was also funded by Celgene and Morphosys. DD was funded by the IZKF Erlangen (project A65) DAV acknowledges research support by the German Research Foundation (DFG VO 1355/5-1) and the Alfried Krupp von Bohlen und Halbach-Stiftung. We would like to acknowledge the excellent assistance of the Core Unit Cell Sorting and Immunomonitoring Erlangen. The present work was performed in partial of the requirements for obtaining the degree “Dr. med”.

Author contributions

LB conceived project, designed the experiments, and wrote the manuscript. MB and DM designed and conducted experiments, helped writing manuscript. MBH selected and evaluated histopathological MM specimens established the immunohistochemical stainings. MJM, DAV, FN, and BS designed experiments and contributed to writing the manuscript. CB, SJ, and HB performed experiments. JN, SB, FB, DG, DD, KG, and FFH provided patient materials, analyzed data, and provided critical suggestions and discussions throughout the study. JTB, FN, RB, MF, CPP, and MH contributed essential reagents/analytical tools and scientific input. AM provided major intellectual input for project design, helped writing the manuscript. HB conceived and directed the project, wrote manuscript.

Author information

Authors and Affiliations

  1. Department of Internal Medicine 5—Hematology/Oncology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany

    Leonhard Busch, Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, Simon Jitschin, Heidi Balzer, Bernd Spriewald, Andreas Mackensen & Heiko Bruns

  2. Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany

    Maike Büttner-Herold

  3. Institute of Bioanalytical Chemistry, Saarland University, Saarbrücken, Germany

    Miriam J. Müller & Dietrich A. Volmer

  4. Department of Dermatology, University of Cologne, Cologne, Germany

    Mario Fabri

  5. Medizinische Klinik I, Saarland University Medical School, Homburg/Saar, Germany

    Jörg T. Bittenbring & Frank Neumann

  6. MorphoSys AG, Planegg, Germany

    Rainer Boxhammer

  7. Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany

    Jens Nolting & Savita Bisht

  8. Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany

    Markus H. Hoffmann

  9. Department of Oncology, Hematology and Stem Cell Transplantation, RWTH Medical School, Aachen, Germany

    Fabian Beier & Deniz Gezer

  10. Department of Dermatology, Laboratory of Dendritic Cell Biology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany

    Diana Dudziak

  11. Department of Trauma Surgery, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany

    Kolja Gelse & Friedrich F. Hennig

  12. Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

    Christian P. Pallasch

Authors
  1. Leonhard Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitrios Mougiakakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maike Büttner-Herold
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miriam J. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dietrich A. Volmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Bach
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mario Fabri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jörg T. Bittenbring
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Frank Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rainer Boxhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jens Nolting
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Savita Bisht
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Martin Böttcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Simon Jitschin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Markus H. Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Heidi Balzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Fabian Beier
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Deniz Gezer
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Diana Dudziak
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Kolja Gelse
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Friedrich F. Hennig
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Christian P. Pallasch
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Bernd Spriewald
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Andreas Mackensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Heiko Bruns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heiko Bruns.

Ethics declarations

Conflict of interest

RB is an employee of Morphosys. HB received research support from Celgene and Morphosys. The remaining authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Busch, L., Mougiakakos, D., Büttner-Herold, M. et al. Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway. Leukemia 32, 2445–2458 (2018). https://doi.org/10.1038/s41375-018-0114-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0114-0

This article is cited by

Search

Advanced search

Quick links